Logo image of BJDX

BLUEJAY DIAGNOSTICS INC (BJDX) Stock Fundamental Analysis

NASDAQ:BJDX - Nasdaq - US0956335097 - Common Stock - Currency: USD

1.69  +0.07 (+4.32%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BJDX. BJDX was compared to 187 industry peers in the Health Care Equipment & Supplies industry. BJDX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BJDX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BJDX had negative earnings in the past year.
BJDX had a negative operating cash flow in the past year.
BJDX had negative earnings in each of the past 5 years.
In the past 5 years BJDX always reported negative operating cash flow.
BJDX Yearly Net Income VS EBIT VS OCF VS FCFBJDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

BJDX has a worse Return On Assets (-387.97%) than 98.93% of its industry peers.
The Return On Equity of BJDX (-529.61%) is worse than 88.24% of its industry peers.
Industry RankSector Rank
ROA -387.97%
ROE -529.61%
ROIC N/A
ROA(3y)-195.93%
ROA(5y)-136.14%
ROE(3y)-263.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BJDX Yearly ROA, ROE, ROICBJDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BJDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BJDX Yearly Profit, Operating, Gross MarginsBJDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, BJDX has more shares outstanding
Compared to 5 years ago, BJDX has less shares outstanding
BJDX has a better debt/assets ratio than last year.
BJDX Yearly Shares OutstandingBJDX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
BJDX Yearly Total Debt VS Total AssetsBJDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -12.30, we must say that BJDX is in the distress zone and has some risk of bankruptcy.
BJDX has a Altman-Z score of -12.30. This is amonst the worse of the industry: BJDX underperforms 83.96% of its industry peers.
BJDX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.00, BJDX is doing good in the industry, outperforming 69.52% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.3
ROIC/WACCN/A
WACCN/A
BJDX Yearly LT Debt VS Equity VS FCFBJDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M 20M

2.3 Liquidity

A Current Ratio of 2.71 indicates that BJDX has no problem at all paying its short term obligations.
The Current ratio of BJDX (2.71) is comparable to the rest of the industry.
A Quick Ratio of 2.71 indicates that BJDX has no problem at all paying its short term obligations.
The Quick ratio of BJDX (2.71) is better than 60.96% of its industry peers.
Industry RankSector Rank
Current Ratio 2.71
Quick Ratio 2.71
BJDX Yearly Current Assets VS Current LiabilitesBJDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 74.16% over the past year.
EPS 1Y (TTM)74.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BJDX will show a very strong growth in Earnings Per Share. The EPS will grow by 30.65% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y67.68%
EPS Next 2Y30.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BJDX Yearly Revenue VS EstimatesBJDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2025 2026 2M 4M 6M 8M
BJDX Yearly EPS VS EstimatesBJDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -500 -1K -1.5K -2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BJDX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BJDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BJDX Price Earnings VS Forward Price EarningsBJDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BJDX Per share dataBJDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150 -200 -250

4.3 Compensation for Growth

BJDX's earnings are expected to grow with 30.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.65%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BJDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLUEJAY DIAGNOSTICS INC

NASDAQ:BJDX (6/30/2025, 3:00:21 PM)

1.69

+0.07 (+4.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-28 2024-03-28/amc
Earnings (Next)N/A N/A
Inst Owners0.64%
Inst Owner Change0.1%
Ins Owners0.04%
Ins Owner Change0%
Market Cap2.52M
Analysts43.33
Price TargetN/A
Short Float %2.26%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.65
P/tB 0.65
EV/EBITDA N/A
EPS(TTM)-295.18
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-4.68
FCFYN/A
OCF(TTM)-4.5
OCFYN/A
SpS0
BVpS2.59
TBVpS2.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -387.97%
ROE -529.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-195.93%
ROA(5y)-136.14%
ROE(3y)-263.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.71
Quick Ratio 2.71
Altman-Z -12.3
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)331.42%
Cap/Depr(5y)201.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.15%
EPS Next Y67.68%
EPS Next 2Y30.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.68%
OCF growth 3YN/A
OCF growth 5YN/A